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Abstract X-linked creatine transport (CRTR) deficiency,
caused by mutations in the SLC6A8 gene, leads to
intellectual disability, speech delay, epilepsy, and autistic
behavior in hemizygous males. Additional diagnostic
features are depleted brain creatine levels and increased
creatine/creatinine ratio (cr/crn) in urine. In heterozygous
females the phenotype is highly variable and diagnostic
hallmarks might be inconclusive. This survey aims to
explore the intrafamilial variability of clinical and brain
proton Magnetic Resonance Spectroscopy (MRS)
findings in males and females with CRTR deficiency.
X-chromosome exome sequencing identified a novel
missense mutation in the SLC6A8 gene (p.G351R) in a
large family with X-linked intellectual disability. Detailed
clinical investigations including neuropsychological
assessment, measurement of in vivo brain creatine con-
centrations using quantitative MRS, and analyses of
creatine metabolites in urine were performed in five
clinically affected family members including three
heterozygous females and one hemizygous male
confirming the diagnosis of CRTR deficiency. The severe
phenotype of the hemizygous male was accompanied by
most distinct aberrations of brain creatine concentrations
(83% in gray and 79% in white matter of age-matched
normal controls) and urinary creatine/creatinine ratio. In
contrast, the heterozygous females showed varying albeit
generally milder phenotypes with less severe brain
creatine (50% to 33% in gray and 45% to none in
white matter) and biochemical urine abnormalities. An
intrafamilial correlation between female phenotype, brain
creatine depletion, and urinary creatine abnormalities was
observed. The combination of powerful new technologies
like exome-next-generation sequencing with thorough
systematic evaluation of patients will further expand the
clinical spectrum of neurometabolic diseases.
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Creatine deficiency syndromes constitute a group of neuro-
metabolic disorders which include two autosomal recessive
conditions with impaired creatine synthesis (arginine gly-
cine amidinotransferase (AGAT) deficiency, OMIM
#612718, and guanidinoacetate methyltransferase (GAMT)
deficiency, OMIM #612736) as well as one X-linked defect
of creatine transport (creatine transport (CRTR) deficiency,
OMIM #300036). The latter is caused by mutations in the
SLC6A8 gene, located on chromosome Xq28 (Longo et al.
2011). Prevalent clinical symptoms of CRTR deficiency are
intellectual disability (ID), expressive speech and language
delay, epilepsy, and autistic behavior (van de Kamp et al.
2013).
CRTR deficiency is a quite common cause of X-linked ID
(XLID) in males with an estimated frequency of 0.3–3.5%
(Arias et al. 2007; Clark et al. 2006). The majority of
affected males with CRTR deficiency present with non-
syndromic ID. However, in some cases mild dysmorphic
features such as mid-facial hypoplasia and short stature
have been described (van de Kamp et al. 2013). Diagnostic
hallmarks in males with CRTR deficiency are a markedly
reduced or absent brain creatine (tCr) signal measured by
proton magnetic resonance spectroscopy (MRS) and an
increased creatine/creatinine (cr/crn) ratio in urine. In
contrast to GAMT deficiency, guanidinoacetate (GAA)
levels in plasma and urine remain within normal range.
To date, numerous mutations in the SLC6A8 gene have
been described (compare Leiden Open Variation Database,
www.lovdnl/slc6a8). According to the X-chromosomal
inheritance, females with heterozygous mutations in the
SLC6A8 gene can be mildly affected or may even be
asymptomatic. The variable phenotype has been ascribed to
the different X-inactivation patterns (van de Kamp et al.
2011). The female phenotypes that have been reported so
far comprise developmental delay as well as mild to
moderate ID. In addition, some affected females show
subtle cerebellar symptoms, behavioral or gastrointestinal
problems, and in one case severe epilepsy (Hahn et al.
2002; Kleefstra et al. 2005; Mancardi et al. 2007;
Mercimek-Mahmutoglu et al. 2010). In females, MRS has
failed to demonstrate an unambiguously reduced tCr signal
(Bizzi et al. 2002; Salomons et al. 2001). Moreover,
elevated cr/crn ratio in urine and impaired creatine uptake
in fibroblasts, the biochemical markers in affected males,
seem unreliable parameters in heterozygous females
(van de Kamp et al. 2011).
Here, we report a large German family with non-
syndromic ID caused by a novel SLC6A8 gene mutation,
which has been detected via thorough sequencing of all
X-chromosome-specific exons. The survey of clinical and
MRS data demonstrates the intrafamilial spectrum of
clinical phenotypes in affected males and females and




A large German family (D150) with intellectually disabled
members in three generations was analyzed (compare family
tree, Fig. 1). One affected male (II.4) with severe ID also had
epilepsy. Two affected males with severe ID lived in
sheltered homes (II.4 and III.4). Craniofacial dysmorphism
was not present in this family. Five family members (four
females: II.2, III.2, IV.1, IV.3 and one male: IV.4) were
studied in detail. The healthy girl (IV.2) with normal
intelligence was excluded from further investigations.
Neuropsychological Assessment
To evaluate intellectual abilities in this family, the Wechsler
Adult Intelligence Test-Third Edition was used for subjects
II.2, III.2, and IV.1. To study subjects IV.3 and IV.4, the
Wechsler Intelligence Scale for Children-Forth Edition was
applied. Mild ID was defined as an IQ score of 50–69 and
moderate ID as an IQ score of 35–49.
Fig. 1 Family tree. Family members of three generations were
affected. Gray symbols represent affected heterozygous females, black
symbols indicate affected males. mut genetic analysis revealed the
mutation p.G351R in the SLC6A8 gene, no mut the familial SLC6A8
mutation was excluded by genetic analysis, n.a. not analyzed, genetic
analysis has not been performed. Subjects II.4 and III.4 are not
included in Table 1. Subject II.4 (age 60 years) is known to suffer
from epilepsy, severe intellectual disability, and to live in a residential
home for disabled people. Subject III.4 (age 37years) is known to
have a severe intellectual disability and lives in a residential home
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Sequencing of X-Chromosome-Specific Exons
Genomic DNA (3 mg) from the index patient (IV.4 in Fig. 1)
was used for constructing a single-end Illumina sequencing
library using the Illumina Genomic DNA Single End Sample
Prep kit, according to the instructions of the manufacturer.
For X-chromosome exome enrichment, we used the Agilent
SureSelect Human X Chromosome Kit, which contains
47,657 RNA baits for 7,591 exons of the human X
chromosome. Single-end deep sequencing was performed
on the Illumina Genome Analyzer GAIIx. Read length was
76 nt. Sequences were analyzed with in-house-developed
tools. Confirmation of the SLC6A8 mutation and segregation
analysis in the family was done by PCR and conventional




Combined MRS/MR-imaging (MRI) examinations were
performed on a 3T clinical whole-body MR system (Magne-
tom Tim Trio, Siemens Healthcare, Erlangen, Germany) with
an 8-channel receive array (Invivo, Gainesville, FL, USA).
The study was approved by the institutional ethics committee.
For single voxel, MRS volumes of interest (VOI) were
selected from T1- and T2-weighted images and positioned in
posterior paramedian cortical gray matter (GM) (12.5 ml), in
frontal (F) as well as parieto-occipital (PO) white matter
(WM) (4.1 ml) (see Fig. 2). Fully relaxed spectra were
obtained in each VOI by applying the short-echo time
stimulated echo acquisition mode (STEAM) sequence
(repetition time/echo time/mixing time: 6000/20/10 ms, 64
accumulations) (Frahm et al. 1989; Natt et al. 2005).
Metabolites considered in this study include creatine and
phosphocreatine (tCr) as ubiquitous compounds linked to
energy metabolism, the neuroaxonal marker N-acetylaspartate
and N-acetylaspartylglutamate (tNAA), choline-containing
compounds (Cho) involved in membrane turnover, and the
glial marker myo-inositol (Ins) (Dreha-Kulaczewski et al.
2009; Pouwels and Frahm 1998). Additionally, GAA,
involved in creatine metabolism, was assessed. The absolute
concentrations of these metabolites were calculated using
LCModel and expressed in mmol/l (Provencher 1993).
Metabolite concentrations were compared to healthy
age- and region-matched control groups from our local
database. Deviations of >2 standard deviations (SD) from
control values were considered significant.
Biochemical Analysis
GAA and cr were measured in urine by gas chromatography–
mass spectrometry with deuterated internal standards as
previously described (Almeida et al. 2004; Arias et al. 2004).
Values were compared to healthy age-matched controls
obtained from a local database.
Results
Clinical and developmental details of six family members
are summarized in Table 1. Two female subjects (IV.1, IV.3
in Fig. 1) had a history of motor and speech delay. No
developmental data were available for the two females II.2
and III.2. Female IV.1 had epilepsy from her 6th to 16th
year of life which was well controlled by valproic acid.
Three females (III.2, IV.1, and IV.3) required special
education due to ID. In addition, aggressive and hyperac-
tive behavior was evident in female subject IV.3. All four
females (II.2, III.2, IV.1, and IV.3) had IQ scores in the mild
ID range (IQ 50–69). The lowest score was reached by
subject III.2.
The affected male (IV.4) presented a delay in motor and
speech development as well as aggressive behavioral
problems. The boy requires special education. Notably,
his IQ score was the lowest of all family members and fell
within the moderate ID range (IQ 35–49).
Genetic Studies
In an effort to identify the pathogenic mutations in families
with XLID collected by the EUROMRX consortium and
Fig. 2 Axial T2-weighted MRI of heterozygous female subject
III.2. MRI demonstrates the placement of VOI in posterior para-
median cortical gray matter and in frontal as well as parieto-occipital
white matter. No signal abnormalities could be detected. Mild































































































































































































































































































































































































































































































































































































































































































































































































































































































































associated groups, we sequenced all X-chromosome
specific exons in the index patient (IV.4 in Fig. 1) of this
large family (D150). After filtering of all identified variants
against publicly available data, including the 1000
Genomes project database, dbSNP135 and the Exome
Variant Server, the only mutation that was predicted to be
deleterious was a missense mutation in SLC6A8 (g.G>A,
chrX:152959802–152959802, UCSC, hg19, p.Gly351Arg,
NP_001136278; p.Gly456Arg, NP_001136277,
p.Gly466Arg, NP_005620). Moreover, this change was
absent in >450 X-chromosome exomes from males with
XLID (data not shown). Subsequently, the presence of
this SLC6A8 mutation was confirmed by PCR using a
gene-specific primer set and Sanger sequencing, and it was
also present in additional affected family members
(Table 1).
Proton MR-Spectroscopy
Spectra from GM and WM of four subjects are shown in
Fig. 3. No distinct tCr peaks could be detected in GM and
WM of the hemizygous male IV.4 (Fig. 3, row A). In the
heterozygous girl IV.3 (Fig. 3, row B) tCr resonances were
evident but decreased when compared to controls (Fig. 3,
row E). The tCr peak heights of the adult heterozygote III.2
(Fig. 3, row C) approximated those of normal controls. By
contrast, the spectra obtained from the female without
SLC6A8 mutation IV.1 (Fig. 3, row D) were unremarkable.
Quantitative analysis of tCr concentrations confirmed the
most distinct reduction (GM 83%, WM 79% of normal
control values in Table 2) in the affected boy (IV.4) (see
Table 1). The tCr levels in the affected heterozygous sister
(IV.3) were also significantly reduced compared to controls,
albeit to a smaller degree (GM 50%, WM 45%). The
heterozygous mother (III.2) showed a significant tCr
decrease (33%) only in GM. The tCr concentrations of
the female (IV.1) without SLC6A8 mutation were within
normal range. The other major metabolites showed no
significant differences in GM compared to controls. In
WM, high levels of tNAA in subjects IV.1 and IV.4 as well
as of Ins in subject IV.1 were found.
No signal clearly arising from GAA (at a chemical shift
of 3.8 ppm) could be detected in any of the subjects’
spectra. With GAA included into the LCModel analysis,
low concentrations of GAA may be fitted in GM only, but
these were comparable to normal controls and thus
regarded an artifact.
The MRI of the hemizygous boy showed an unspecific
small, hyperintense lesion on T2-weighted images within
the left basal ganglia. Mild cerebellar vermis atrophy was
detectable on the MRI of the heterozygous female subject
III.2 and slightly more pronounced on the MR images of
her daughter (IV.1) without SLC6A8 mutation.
Biochemical Analysis
Notably, the most pronounced increase of cr/crn urinary
level was measured in the hemizygous boy (IV.4). The
comparatively much lower ratio of his heterozygous sister
(IV.3) (Table 1) was still elevated with respect to her age-
matched control group (Table 2). Their heterozygous
mother (III.2) as well as the half-sister without SLC6A8
mutation (IV.1) had normal cr/crn ratios. Urinary excretion
of GAA was within normal ranges in all subjects.
Discussion
In a large family with non-syndromic XLID,
X-chromosome exome screening revealed a novel mutation
in the SLC6A8 gene (p.G351R, NP_001136278) leading to
CRTR deficiency syndrome. The diagnosis of CRTR
deficiency was subsequently confirmed by MRS of the
brain as well as urinary creatine/creatinine measurement in
three affected females and one affected male. The pheno-
typic variability within this family is in line with numerous
reports about the broad range of clinical presentations in
this neurometabolic disease (deGrauw et al. 2003; van de
Kamp et al. 2013). Profound ID was evident in all male
members. The hemizygous male index patient presented
with the characteristic severe phenotype comprising ID as
well as severe speech delay and behavioral disturbances.
All heterozygous females showed milder symptoms. Their
IQs ranged from 50–62 (Table 1). However, the familial
SLC6A8 mutation was excluded in one half-sister (IV.1) of
the index patient, who presented with mild ID and epilepsy.
This half-sister has a different and also intellectually
disabled father than subjects IV.2-IV.4 and therefore may
be affected with ID of another origin. Cerebellar signs or
gastrointestinal problems like chronic constipation, ileus, or
megacolon, which had previously been reported in affected
males and females (Kleefstra et al. 2005; van de Kamp
et al. 2011), were not present in our family. Moreover,
no affected family member had obvious craniofacial
dysmorphism.
In the clinical setting, CRTR deficiency is usually
diagnosed via a screening test in urine, which shows a
strong elevation of the cr/crn ratio in affected males. In our
index patient, cr/crn ratio screening in urine was problematic
since he rejected urine sampling several times and wore
diapers. The missense mutation in the SLC6A8 gene was
detected via X-chromosome exome sequencing. Subse-
quently, the cr/crn ratios were evaluated in all affected
heterozygous females. Interestingly, only one of the three
heterozygous females had a mild increase of the urinary
cr/crn ratio. Remarkably, this female patient also presented
with the lowest brain tCr levels and had a more severe
JIMD Reports
Fig. 3 Single voxel proton MR spectra from gray and white
matter of affected family members with CRTR deficiency. (Row
A) male subject IV.4 hemizygous for SLC6A8 mutation. (row B)
female subject IV.3 heterozygous for SLC6A8 mutation. (Row C)
female subject III.2 heterozygous for SLC6A8 mutation. (Row D)
female subject IV.1 without mutation. (Row E) healthy control subject
(female, age 13 years). Note the variability of tCr (sum of creatine and
phosphocreatine) peaks at 3.2 and 3.9 ppm between subjects. In row A
no defined tCr peaks can be detected, whereas in row B they are
clearly visible but reduced compared to controls (row E). In row C
and D the tCr peaks are of normal heights compared to controls.
Assignments of main peaks of the proton MR spectrum are added to
the control spectra (row E). Note that scale of spectra varies to
facilitate qualitative assessment of differences of tCr peak heights.
tNAA sum of N-acetylaspartate and N-acetylaspartylglutamate, Cho
choline-containing compounds, Ins myo-inositol
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phenotype comprising behavioral disturbances. This obser-
vation is in line with a correlation between clinical
phenotype, cerebral tCr depletion and elevation of urinary
cr/crn ratio postulated by van de Kamp et al (van de Kamp
et al. 2011). However, a strict correlation between brain
MRS or biochemical data and IQ scores, as suggested, has
not been found in the heterozygous females with CRTR
deficiency described here. Yet, an inverse correlation
between cerebral tCr concentrations and urinary cr/crn ratios
could be seen. The small sample size precluded further
statistical analysis.
CRTR deficiency syndromes are increasingly detected
among patients with non-syndromic unexplained ID (Clark
et al. 2006; Lion-Francois et al. 2006; Rosenberg et al.
2004). In contrast, defects in creatine synthesis seem to be
much less frequent. In affected females, it is difficult to
diagnose CRTR deficiency via urine analysis. In our study,
a significant elevation of cr/crn ratio in urine analysis was
only found in one affected female.
We performed a quantitative brain MRS study in this
family on both affected genders of two generations, which
revealed significant reduction of brain tCr concentration in
the GM of all family members with the SLC6A8 gene
mutation. In WM of the adult heterozygous female the
concentration of tCr remained within normal ranges (see
Table 1). The hemizygous male index patient IV.4 (Fig. 2,
row A) showed almost complete absence of the tCr peaks
in both GM and WM, which corresponds to previous
reports (van de Kamp et al. 2013). The disparity of the tCr
reduction among the heterozygous females within the same
family, however, is a remarkable finding. The youngest girl
with SLC6A8 mutation showed a distinct tCr decrease,
which was already qualitatively appreciable in the spec-
tra (Fig. 2, row B) and subsequently confirmed by
quantification. In contrast, the slighter tCr reduction in
GM of the heterozygous mother has not been evident in the
spectral pattern but was disclosed only as a result of the
quantification (Fig. 2, row C). The tCr concentrations in
one half-sister of the index patient, in whom the familial
SLC6A8 mutation was excluded, were within normal limits
(Fig. 2, row D) as expected.
To date, quantitative brain MRS data of heterozygous
females with CRTR deficiency have only been included in
a minority of reports. Most publications are restricted to
the qualitative description of a reduced peak of total
creatine (tCr) in the spectrum (Cecil et al. 2003; deGrauw
et al. 2003; Salomons et al. 2001). Dezertova et al. (2008)
verified a decreased tCr concentration in an affected female
only after quantification, thus emphasizing the importance
of quantitative MRS. On the other hand, another
quantitative MRS study of a cohort of eight female
heterozygotes revealed a significant tCr reduction only on






























































































































































































































































































































































































































































































creatine concentrations were within normal ranges regard-
less of the region, a finding that is consistent with our
results. The observation of a GAA signal as described by
Sijens et al. (2005) could not be confirmed in our study.
The small unspecific hyperintense lesion in the basal
ganglia seen on T2-weighted MR images of the boy is
consistent with a hamartoma. The atrophy of cerebellar
vermis has been detected in female family members with as
well as without SLC6A8 mutation and thus is considered as
unspecific.
Several therapeutic trials using creatine monohydrate,
L-arginine, and glycine have so far failed to reliably
improve cerebral tCr levels and/or clinical symptoms in
patients with CRTR deficiency (van de Kamp et al. 2012).
However, brain-specific Slc6a8 knockout mice, an animal
model of human CRTR deficiency, were treated with the
creatine analog cyclocreatine and did indeed show
improved cognition as recently reported by Kurosawa
et al. (2012). The authors were also able to demonstrate
that the cyclocreatine entered the mouse brain and was
successfully funneled into its metabolism. Thus, further
studies using this promising therapy approach are warranted
to assess its implications for humans.
Conclusion
In a large family with X-linked intellectual disability of
unknown cause, the novel SLC6A8 mutation p.G351R
was detected via X-chromosome exome sequencing. The
diagnosis of CRTR deficiency was confirmed by MRS of
the brain as well as urinary creatine/creatinine measure-
ment, thus underlining the pathogenicity of this novel
SLC6A8 mutation. Female phenotypes heterozygous for the
mutation varied significantly even within one family.
However, a correlation between severity of clinical
symptoms, brain creatine depletion and urinary creatine
abnormalities could be observed.
The combination of powerful new technologies like
exome-next-generation sequencing with thorough
systematic evaluation of patients as in this study will work
synergistically to further expand our knowledge of the
clinical spectrum of neurometabolic diseases.
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Synopsis
The combination of the powerful technology exome-next-
generation sequencing with thorough systematic clinical
evaluation of patients, as in this study of a family
with X-linked creatine transport deficiency, will work
synergistically to further expand the clinical spectrum of
neurometabolic diseases.
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